The conversation is about the stability of pyrilutamide in different solutions. The user is asking if a 70/30 ethanol/pg solution with 4% water will degrade pyrilutamide.
PP405 is a new hair loss treatment facing mixed reactions due to initial hype and insufficient data. Some are hopeful, but many doubt its effectiveness compared to minoxidil and finasteride.
The conversation discusses the effectiveness of Dutasteride (DUT) and Finasteride (FIN) for hair loss. Users share varied experiences, with some finding DUT more effective and others experiencing side effects or no change, highlighting that individual responses can vary.
Scalp sunburns can cause permanent hair loss, so wearing UPF hats is essential. Tretinoin and Tacrolimus users should be cautious of increased photosensitivity and potential scalp issues.
A 16 year old's experience with using pyrilutamide to treat hair loss, and the potential side effects of adding tretinoin to minoxidil and finasteride treatments.
The conversation is about choosing a topical antiandrogen for hair loss, with options including RU58841, CB0301, Pyrolutamide, Alfatradiol, and Fluridil. Users discuss their preferences and reasons for selecting specific treatments.
A user is considering switching from finasteride to dutasteride due to unsatisfactory results and is concerned about experiencing another shedding phase. Another user recently made the switch and will update on their experience.
Bimatoprost is preferred over Latanoprost for hair growth. Users are seeking a reliable supplier for raw Bimatoprost powder to make their own topical solution.
A person had a successful hair transplant in Turkey with 3200 grafts using FUE and DHI techniques, and is satisfied with the results after 9 months. They have been using finasteride for 7 years to maintain hair health.
A user's progress pictures showing the results of taking Fin (0.5 mg per day), Min (5 mg per day) and microneedling with Dr. Pen Ultima M8; another user asked when the regrowth was noticed, and commented on the hair appearing darker.
The user is considering using P5P to reduce high prolactin levels and is questioning if oral minoxidil could be contributing to the issue. They are also debating whether to switch from oral to topical minoxidil.
A user's experience with hair loss and scalp inflammation, which was alleviated by using RU58841 along with finasteride and dutasteride. A theory of inflammation possibly being a cause of hairloss is also discussed.
The user is concerned about the legitimacy of online-bought Dutasteride due to its sugary taste and increased urination. Others suggest it looks legitimate but recommend consulting a doctor and possibly testing DHT levels.
RU58841 is a controversial hair loss treatment with mixed reviews; some users report success, often in combination with other treatments like finasteride or minoxidil, while others experience side effects like chest pain. The treatment's discontinuation is speculated to be due to patent expiration and lack of profitability, despite some users continuing to use it as part of a broader regimen.
The conversation is about finding reputable clinics in Canada or near the US border that offer DUT mesotherapy for hair loss. The user is seeking recommendations and cost information for these treatments.
RU58841 is discussed as a treatment that stops scalp itching when used with finasteride or dutasteride. The user is considering trying RU58841 due to persistent itching despite using the "big 3" treatments.
The conversation discusses the delay in the release of a new hair loss treatment, Pyrilutamide, and speculates on potential safety concerns as a reason for the delay. It also mentions GT20029 as another future treatment option, with a release at least five years away, and touches on the avoidance of research chemicals due to uncertainty about their authenticity.
The user is using oral minoxidil for hair growth and is considering adding topical latanoprost, but is concerned about potential eye color change. They are seeking advice on the effectiveness of latanoprost for hair thickening and the risk of eye color change.
The conversation discusses the effectiveness of adding RCP (redensyl, capixyl, procapil) to a hair loss treatment regimen that includes minoxidil and finasteride. Users share experiences, suggesting RCP may not be as effective as minoxidil, but could be useful for creating topical solutions.
PP405, a potential treatment for male pattern baldness, shows promise with some participants experiencing hair regrowth in early trials. However, it is not yet considered a cure and may be used alongside existing treatments like minoxidil and finasteride.
RU58841 is preferred over finasteride for blocking DHT on the scalp, especially for those with aggressive MPB. Creatine is associated with increased hair shedding, even when using RU58841.
The post discusses a user's 2-month progress in treating hair loss using topical Du once a week, microneedling, and red light therapy. The user notes that red light therapy is primarily for face and body inflammation but also applies it to the scalp.
PP405 is a potential hair loss treatment that may reactivate dormant hair follicles, with Phase 3 trials expected. Some users are cautious, suggesting using finasteride in the meantime, while others are skeptical about PP405's effectiveness.
The conversation discusses using hair follicle dermal papilla exosomes for hair loss treatment. It inquires about purchasing options for this treatment.
RU58841 users discuss increasing dosage for better hair regrowth, with some considering adding minoxidil and finasteride. Users report mixed results, with some experiencing side effects at higher doses.
Kintor is accused of using fake pictures to promote their product, Pyrilutamide (KX826), which failed Phase 3 trials. Users express disappointment and note similar false advertising has occurred with finasteride and minoxidil.
People are discussing the anticipated release of PP405 phase 2a results, expected by the end of March, with some skepticism about its effectiveness. There is cautious optimism due to past experiences with similar treatments like Breezula, despite concerns about the lack of presentation at the AAD 2026 conference.